Academic, Government and Industry Leaders Choose MammaPrint as the Biomarker of Choice for the I-SPY 2 Breast Cancer Clinical Trial

I-SPY 2 is managed by the Biomarkers Consortium whose members include government and industry leaders such as:

  • United States Food and Drug Administration (FDA)
  • National Institutes of Health (NIH)
  • National Cancer Institute (NCI)
  • Abbott
  • Amgen
  • Pfizer
  • Johnson & Johnson
  • Genentech Inc., unit of Roche
  • Eli Lilly and Co.
  • Sentinelle Medical Inc.


Trial Coordination:

Foundation for the National Institutes of Health
9650 Rockville Pike
Bethesda, MD 20814-3999
Phone: (301) 402-5311
Fax: (301) 480-2752
Email: foundation@fnih.org


Principle Investigators:

Laura Esserman, MD, MBA
Director, Carol Franc Buck Breast Care Center
Helen Diller Family Comprehensive Cancer Center
University of California at San Francisco 

Donald Berry, PhD
Chairman of the Department of Biostatistics
University of Texas MD Anderson Cancer Center


Study Objectives:

Serve as a model for integrating biomarkers, adaptive trial designs and bioinformatics to quickly, inexpensively and simultaneously test multiple drug candidates, thereby accelerating the development and commercialization of compounds for locally advanced breast cancer.

For additional information on I-SPY clinical trial please visit:

  1. I-SPY 2.org  Breast Cancer Clinical Trial

  2. National Cancer Institute's I-SPY 2 Breast Cancer Clinical Trial at cancer.gov

  3. Foundation of the National Institute of Health's Biomarkers Consortium I-SPY 2 Breast Cancer Clinical Trial


To inquire about participation in the I-SPY trial, please contact Agendia Clinical Trials.

I-SPY 2: An Adaptive Breast Cancer Trial Design in the Setting of Neoadjuvant Chemotherapy
Click to enlarge image


I-SPY 2: An Adaptive Breast Cancer Trial Design in the Setting of Neoadjuvant Chemotherapy
Click to enlarge image